These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 11772120)

  • 21. Decaffeinated coffee and nicotine-free tobacco provide neuroprotection in Drosophila models of Parkinson's disease through an NRF2-dependent mechanism.
    Trinh K; Andrews L; Krause J; Hanak T; Lee D; Gelb M; Pallanck L
    J Neurosci; 2010 Apr; 30(16):5525-32. PubMed ID: 20410106
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Berberine prevents nigrostriatal dopaminergic neuronal loss and suppresses hippocampal apoptosis in mice with Parkinson's disease.
    Kim M; Cho KH; Shin MS; Lee JM; Cho HS; Kim CJ; Shin DH; Yang HJ
    Int J Mol Med; 2014 Apr; 33(4):870-8. PubMed ID: 24535622
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Striatal increase of neurotrophic factors as a mechanism of nicotine protection in experimental parkinsonism.
    Maggio R; Riva M; Vaglini F; Fornai F; Racagni G; Corsini GU
    J Neural Transm (Vienna); 1997; 104(10):1113-23. PubMed ID: 9503263
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson's disease.
    Popat RA; Van Den Eeden SK; Tanner CM; Kamel F; Umbach DM; Marder K; Mayeux R; Ritz B; Ross GW; Petrovitch H; Topol B; McGuire V; Costello S; Manthripragada AD; Southwick A; Myers RM; Nelson LM
    Eur J Neurol; 2011 May; 18(5):756-65. PubMed ID: 21281405
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.
    Pinna A; Tronci E; Schintu N; Simola N; Volpini R; Pontis S; Cristalli G; Morelli M
    Neuropharmacology; 2010 Mar; 58(3):613-23. PubMed ID: 19951715
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nicotine and Nicotinic Receptor Drugs: Potential for Parkinson's Disease and Drug-Induced Movement Disorders.
    Quik M; Bordia T; Zhang D; Perez XA
    Int Rev Neurobiol; 2015; 124():247-71. PubMed ID: 26472532
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Do caffeine and more selective adenosine A
    Chen JF; Schwarzschild MA
    Parkinsonism Relat Disord; 2020 Nov; 80 Suppl 1(Suppl 1):S45-S53. PubMed ID: 33349580
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuroprotective effect of nicotine on dopaminergic neurons by anti-inflammatory action.
    Park HJ; Lee PH; Ahn YW; Choi YJ; Lee G; Lee DY; Chung ES; Jin BK
    Eur J Neurosci; 2007 Jul; 26(1):79-89. PubMed ID: 17581257
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanisms of MPTP toxicity and their implications for therapy of Parkinson's disease.
    Watanabe Y; Himeda T; Araki T
    Med Sci Monit; 2005 Jan; 11(1):RA17-23. PubMed ID: 15614202
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EGb761 protects against nigrostriatal dopaminergic neurotoxicity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice: role of oxidative stress.
    Rojas P; Serrano-García N; Mares-Sámano JJ; Medina-Campos ON; Pedraza-Chaverri J; Ogren SO
    Eur J Neurosci; 2008 Jul; 28(1):41-50. PubMed ID: 18662333
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lutein protects dopaminergic neurons against MPTP-induced apoptotic death and motor dysfunction by ameliorating mitochondrial disruption and oxidative stress.
    Nataraj J; Manivasagam T; Thenmozhi AJ; Essa MM
    Nutr Neurosci; 2016 Jul; 19(6):237-46. PubMed ID: 25730317
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pathophysiological roles for purines: adenosine, caffeine and urate.
    Morelli M; Carta AR; Kachroo A; Schwarzschild MA
    Prog Brain Res; 2010; 183():183-208. PubMed ID: 20696321
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Can calcium antagonists provide a neuroprotective effect in Parkinson's disease?
    Rodnitzky RL
    Drugs; 1999 Jun; 57(6):845-9. PubMed ID: 10400399
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nicotinic receptors as CNS targets for Parkinson's disease.
    Quik M; Bordia T; O'Leary K
    Biochem Pharmacol; 2007 Oct; 74(8):1224-34. PubMed ID: 17631864
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives.
    Sarkar S; Raymick J; Imam S
    Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27338353
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nimodipine, an L-type calcium channel blocker attenuates mitochondrial dysfunctions to protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.
    Singh A; Verma P; Balaji G; Samantaray S; Mohanakumar KP
    Neurochem Int; 2016 Oct; 99():221-232. PubMed ID: 27395789
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuroprotective effects of umbelliferone and esculetin in a mouse model of Parkinson's disease.
    Subramaniam SR; Ellis EM
    J Neurosci Res; 2013 Mar; 91(3):453-61. PubMed ID: 23184853
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuroprotective effects of stemazole in the MPTP-induced acute model of Parkinson's disease: Involvement of the dopamine system.
    Guo Z; Xu S; Du N; Liu J; Huang Y; Han M
    Neurosci Lett; 2016 Mar; 616():152-9. PubMed ID: 26827716
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Caffeine: An Overview of Its Beneficial Effects in Experimental Models and Clinical Trials of Parkinson's Disease.
    Schepici G; Silvestro S; Bramanti P; Mazzon E
    Int J Mol Sci; 2020 Jul; 21(13):. PubMed ID: 32635541
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neuroprotective effect of protein kinase C delta inhibitor rottlerin in cell culture and animal models of Parkinson's disease.
    Zhang D; Anantharam V; Kanthasamy A; Kanthasamy AG
    J Pharmacol Exp Ther; 2007 Sep; 322(3):913-22. PubMed ID: 17565007
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.